HR Execs on the Move

Angion is a late-stage clinical company developing small molecules targeting acute organ injury and chronic fibrosis.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • 51 Charles Lindbergh Blvd
    Uniondale, NY USA 11553
  • Phone: 516.326.1200


Name Title Contact Details
Daniel Iazzetti
Vice President of Human Resources Profile

Similar Companies

Polyplus Transfection

Polyplus Transfection is a San Marcos, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

SelectX Pharmaceuticals

SelectX Pharmaceuticals, Inc. is a Worcester, MA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Epinex Diagnostics

Epinex Diagnostics is a Tustin, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Gossamer Bio

Gossamer Bio is a San Diego-based company focused on the discovery and development of novel and differentiated therapeutic products, to address high unmet needs amongst various targeted patient populations. Founded by the former Receptos executive team, Gossamer Bio`s strategy will be to leverage an asset-rich in-licensing environment, with a focus on areas of high unmet need,

Antibe Therapeutics

Antibe Therapeutics develops safer medications for chronic pain and inflammation. Today, physicians and consumers rely principally on non-steroidal anti-inflammatory drugs (NSAIDs), a $12 billion category of medications that includes brands like Advil, Aleve, Motrin, Celebrex, Voltaren and Aspirin. While effective, NSAIDs can cause gastrointestinal damage and bleeding. To address this serious medical need, Antibe has patented a technology for linking NSAID molecules to hydrogen sulfide molecules. More than a decade of academic and applied research has demonstrated that hydrogen sulfide, when appropriately delivered, can protect the gastrointestinal tract and enhance the anti-inflammatory effectiveness of today’s NSAIDs. Beginning with its IPO in mid-2013, Antibe has raised more than $10 million and initiated human clinical trials of its first drug, aimed at mild to moderate pain.